[Image] Antibody-drug conjugates (ADCs) are a class of emerging anti-cancer drugs that can directly deliver highly cytotoxic molecules to cancer cells. To date, 12 ADC drugs have received market approval. ADCs are formed by the covalent linkage of monoclonal antibodies and cytotoxins through linkers. Research indicates that linkers play a crucial role in ADC drugs, as their properties significantly affect the therapeutic index of these drugs…